Introduction: A life-threatening respiratory disease, coronavirus 2019 (COVID-19), has spread across the globe since December 2019. Many prognostic factors have already been put forward to predict the risk of death and other outcomes. The current study is evaluating the survival rate between hypertensive and non-hypertensive infected patients. Methods: Patients who were included in this study were admitted between 20 February to 1 March 2020 in Fars (southwest of Iran) province hospitals. Data were collected from the electronic base registry which contained demographic information, medical symptoms, and signs, underlying diseases, CT scan results, and final outcome. Results: Of all 1239 positive cases, 159 (12.83%) had known with hypertension ant this group was significantly older than non-hypertensive patients (66.1 years Vs 48.95 years, p < .001). According to Kaplan-Meier survival curve and log-rank test, it was seen hypertensive patients deteriorated more rapidly than non-hypertensive group (p = .032). Moreover, HIV, cardiovascular, and kidney disease were diagnosed as factors that increase the risk of death in hypertensive patients. Conclusion: The current study about the survival rate of COVID-19 patients had shown hypertensive patents are in danger of disease severity, although it may be related to their age. Moreover, the probability of other complications like diabetes, smoking, asthma, kidney, and cardiovascular diseases, and either some other infections such as HIV can make the condition complicated and need more consideration to prevent noxious outcomes.
View related articles View Crossmark data Citing articles: 1 View citing articles Characteristics of deceased patients with CoVID-19 after the first peak of the epidemic in Fars province, Iran
Background: Identifying effective biomarkers plays a critical role on screening; rapid diagnosis; proper managements and therapeutic options, which is helpful in preventing serious complications. The present study aimed to compare the liver laboratory tests between alive and dead hospitalized cases for prediction and proper management of the patients. Methods: This retrospective, cross sectional study consists of all deceased patients admitted in one center in Shiraz, Iran during 19 Feb 2020 to 22 Aug 2021. For further comparison, we selected a 1:2 ratios alive group randomly. Results: Overall, 875 hospitalized cases died due to COVID-19. We selected 1750 alive group randomly. The median age was significantly higher in died group (65.96 vs 51.20). Regarding the laboratory findings during the hospitalization ALT, AST, Bili.D were significantly higher in non-survivors than survivors but Albumin was less in deceased patients. It was revealed elevated levels of Albumin, AST, Bili.T and Bili.D were associated with increasing the risk of in hospital death. Moreover, the predictive effect of ALP and Bili.D had significantly more than others with high sensitivity and specify. Conclusion: We found patients with COVID-19 have reduced serum albumin level, and increase ALT and AST. The current results revealed abnormal liver chemistries is associated with poor outcome, which highlighted the importance of monitoring these patients more carefully and should be given more caution.
Introduction: Serological assay has critical role in defining immunity based on seroprevalence. Identifying the extend of seropositivity would determine the truly infected cases. Method: We conducted serologic testing for SARS-COV-2 antibodies in 492 health care workers (HCWs) before vaccination program in Shiraz, Iran (30 April 2020). Results: Based on job position, cases were divided into two categories: frontline staff (169, 34.34%) and non-front-line staff (323, 65.65%). Of all cases 40.65 were female and the rest of them were male. Mean age was estimated 47.97 ± 109.20 and 38.98 ± 8.76 in high risk and low risk population respectively (P = 0.1). In total 367 (74.59%) subjects reported to suffered at least one of the COVID-19 symptoms. More than half of cases (73.57) had history of COVID-19 disease within six months before this survey. No relation was seen between blood type and immunoglobulin positivity. Seropositivity prevalence in low risk and high-risk populations were estimated 8.0 (95% CI: 1.0-16.8) and 5.2(95% CI: 1.2-9.8) respectively. The immunoglobulin test for SARS-COV-2 revealed that 64 (64/492, 13%) and 37 (37/492, 7.52%) subjects had IgG and IgM antibodies against the virus. 14 (14/169, 8.28%) individuals who had IgM were frontline health workers, this is while 23 (14/323, 7.12%) were non front lineConclusion: The findings of this study imply that seropositivity was lower in non-frontline health care staff. Furthermore, there was no association between blood type and seropositivity. Therefore, the knowledge of antibody status may help into overcome fears in clinical staff, and also more attention is need for interpreting the levels of anti-SARS-CoV-2 antibodies to make a clinical diagnosis of COVID-19, since the time of expose and time of test is an important point which should be considered in the issue.
Background: Influenza is one of the most important viral diseases with high mortality and morbidity that can have a great impact on public health and economy. Objective: To investigate the clinical and epidemiological features of influenza virus A/H1N1, A/H3N2, and B infection in Fars province, southern Iran, in 2015-2019. Methods: In this retrospective cross-sectional study, we assessed the archived data of
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.